Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial.

Original post:
Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

Scroll to Top